Login

Carisma Therapeutics Inc. 8-K SEC Filings

Filed On Filing
05 Dec 2025 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule; Departure/Election of Directors or Officers; Compensation

As previously disclosed, the common stock, $0.001 par value per share (the “Common Stock”) of Carisma Therapeutics Inc. (the “Company”) was suspended from trading on The Nasdaq Stock Market LLC (“Nasdaq”) effective at the open of busines...

15 Oct 2025 8-K: Departure/Election of Directors or Officers; Compensation

In connection with the termination of your employment with Carisma Therapeutics Inc. (the “Company”) on October 15, 2025 (the “Separation Date”), you are eligible to receive Severance Benefits as described in Section 8 of the employment ...

09 Oct 2025 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

On October 9, 2025, Carisma Therapeutics Inc. (the “Company”) received a delisting determination letter (the “Determination Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”). The Determination Letter indicated that, as a result of the...

18 Sep 2025 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +1 more

On September 16, 2025 (the “Amendment Effective Date”), Carisma Therapeutics Inc. (the “Company”) and ModernaTX, Inc. (“Moderna”) entered into a First Amendment to the Collaboration and License Agreement (the “Amendment”), which amends t...

29 Aug 2025 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +3 more

THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”), is made as of August 29, 2025 and amends and restates the Employment Agreement (the “Prior Agreement”) dated March 7, 2023, by and between Carisma Therapeutics Inc., a Del...

08 Aug 2025 8-K: Submission of Matters to a Vote of Security Holders

On August 5, 2025, Carisma Therapeutics Inc. (the “Company”) held a Special Meeting of Stockholders (the “Special Meeting”). The following is a summary of the matters voted on at the Special Meeting.

15 Jul 2025 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

As previously disclosed, on January 6, 2025, The Nasdaq Stock Market LLC (“Nasdaq”) notified Carisma Therapeutics Inc. (the “Company”) that, based upon the preceding 30-business day period, the Company no longer satisfied Nasdaq Listing ...

23 Jun 2025 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

THIS CONTINGENT VALUE RIGHTS AGREEMENT (this “Agreement”), dated as of [●], 2025, is entered into by and between Carisma Therapeutics Inc., a Delaware corporation (“Parent”), and Computershare Inc. a Delaware corporation (“Computershare”...

12 Jun 2025 8-K: Other Events

On June 10, 2025, Carisma Therapeutics Inc. (the “Company”) received written notice from The Nasdaq Stock Market LLC (“Nasdaq”) that a Nasdaq Hearings Panel (the “Panel”) has determined to grant the request of the Company to continue its...

16 Apr 2025 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

As previously disclosed, on October 10, 2024, Carisma Therapeutics Inc. (the “Company”) received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company no longer sa...

13 Jan 2025 8-K: Other Events

On January 13, 2025, Carisma Therapeutics Inc. (the “Company”) will be posting an updated corporate presentation under “Corporate Presentation” on the “For Investors” section of the Company’s website (www.carismatx.com). The information ...

10 Jan 2025 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

On January 6, 2025, Carisma Therapeutics Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based upon the closing ...

26 Dec 2024 8-K: Departure/Election of Directors or Officers; Compensation

This Master Services Agreement (the “Agreement”) is made effective as of January 1, 2025 (the “Effective Date”), by and between Carisma Therapeutics Inc., a Delaware corporation, with its principal place of business being 3675 Market Str...

09 Dec 2024 8-K: Costs Associated with Exit or Disposal Activities; Departure/Election of Directors or Officers; Compensation +1 more

On December 7, 2024, after consideration by the board of directors of Carisma Therapeutics Inc. (the “Company”) of the Company’s current cash runway and operating plan, the board of directors approved a revised operating plan, which incl...

07 Nov 2024 8-K: Results of Operations and Financial Condition

Initial results from the Phase 1 study of CT-0525, lead product candidate, expected in the first quarter of 2025

30 Oct 2024 8-K: Departure/Election of Directors or Officers; Compensation

On October 24, 2024, Michael Torok notified Carisma Therapeutics Inc. (the “Company”) of his decision to resign from the Company’s board of directors (the “Board”), effective October 31, 2024. At the time of his resignation, Mr. Torok wa...

11 Oct 2024 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

On October 10, 2024, Carisma Therapeutics Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications I Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Company is not in...

08 Aug 2024 8-K: Results of Operations and Financial Condition

Initial data for CT-0525, lead product candidate for anti-HER2 program, expected by year-end 2024

09 Jul 2024 8-K: Other Events

1 Clinical Activity Observed in HER2 3+ Patients Correlation of target expression and clinical activity supports mechanism of action Change in tumor ctDNA at week 4 based on HER2 status: % change in ctDNA 1 * BOR of SD per RECIST v1.1 HE...

02 Jul 2024 8-K: Costs Associated with Exit or Disposal Activities

On June 26, 2024, in furtherance of its revised operating plan, Carisma Therapeutics Inc. (the “Company”) notified Novartis Pharmaceuticals Corporation (“Novartis”) of its termination of the Company’s Manufacturing and Supply Agreement, ...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support